
Daily Derm Times: March 26, 2025
Key Takeaways
- Monoclonal antibodies targeting type 2 cytokines have transformed inflammatory skin disease treatment, enhancing symptom management and patient quality of life.
- A new moisturizing formulation effectively repairs skin post-microneedling, improving texture and reducing erythema.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Journal Digest: March 26
This review of the latest dermatologic studies includes insights into atopic dermatitis, including results from a novel topical CBD application, skin mycobiome comparison, and more.
Unraveling Type 2 Inflammation in Skin Diseases
Targeting type 2 cytokines with monoclonal antibodies has revolutionized treatment for inflammatory skin diseases, reducing symptoms and improving quality of life.
Novel Moisturizing Formulation is Effective for Repairing Skin After Microneedling
When compared to a non-active product, the formula improved texture, reduced erythema, and strengthened the skin barrier.
An Up-to-Date Review of Rosacea in Childhood and Adolescence
Researchers behind a recent review shared expert insights, treatment guidelines, and differential diagnosis techniques for pediatric rosacea.
Active Education Outperforms Passive Approaches in Melanoma Detection by Non-Medical Individuals
A study shows active educational interventions improve melanoma detection rates and rule application, with lasting effects over time.
CBD and CBG Ointment Improved Skin in Patients with Atopic Dermatitis
Use of the product showed positive changes in the skin’s hydration, lipid content, transepidermal water loss, and erythema.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















